PhaBuilder

About PhaBuilder

PhaBuilder, established in February 2021, operates at the forefront of synthetic biotechnology, leveraging decades of academic research to create commercially viable bioplastics and other high-value chemicals. The company was founded by Professor Guoqiang Chen, a distinguished expert in synthetic biology from Tsinghua University, along with his former students Yuxuan Lan and Fuqing Wu. Professor Chen's 30-year career dedicated to microbial engineering, including early collaborations with industry pioneers like Imperial Chemical Industries and Procter & Gamble, forms the technological bedrock of the company.

The core of PhaBuilder's business is the production of Polyhydroxyalkanoates (PHA), a type of biopolymer synthesized by microorganisms that is both biocompatible and fully biodegradable. Unlike traditional plastics, PHA materials decompose into water and carbon dioxide, offering a compelling solution to plastic pollution. The company's business model is centered on its proprietary "Next Generation Industrial Biotechnology (NGIB)" platform, which utilizes engineered halophilic (salt-loving) bacteria. This approach reportedly simplifies the production process by enabling non-sterile, continuous fermentation, which can reduce equipment costs by 30% and energy consumption by over 50%. PhaBuilder serves a diverse client base by providing PHA resins and developing specific formulations for various industries, including packaging, medical devices, 3D printing, and textiles.

PhaBuilder is scaling its operations aggressively, with a flexible intelligent manufacturing plant in Beijing and a larger 10,000-tonne per annum facility under construction in Hubei, which is expected to begin production in early 2025. This is part of a broader strategy to establish multiple large-scale production bases. The company's product strategy, termed "4P," encompasses expanding its family of PHA materials (PHAmily), developing application solutions (PHAbrary), scaling industrial production (PHAdustry), and promoting a green lifestyle through commercial products (PHA Life). Beyond PHA, the company also develops other valuable chemicals such as ectoine and cadaverine. The venture has attracted significant investment from notable firms including Sequoia China, Kunlun Capital, and the China State-owned Enterprise Mixed Ownership Reform Fund, securing over $90 million in multiple funding rounds to fuel its expansion and R&D efforts.